ANRIL is implicated in many malignancies, including cancers of the bladder (77), ovary (78, 79), lung (38, 58, 80–82), liver (40, 54, 83), stomach (22), breast (57, 84, 85), esophagus (86), nasopharyngeal cavity (39, 87, 88), thyroid (89), bone (90), cervix (91), colon (92), prostate (21, 56), glioma (55), and others (76). This evidence concerns the gene CDKN2B-AS1 and glioma.